These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35491829)

  • 1. Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
    Lai MT; Feng M; Xu M; Ngo W; Diamond TL; Hwang C; Grobler JA; Hazuda DJ; Asante-Appiah E
    Antimicrob Agents Chemother; 2022 May; 66(5):e0222321. PubMed ID: 35491829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
    Diamond TL; Ngo W; Xu M; Goh SL; Rodriguez S; Lai MT; Asante-Appiah E; Grobler JA
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0013322. PubMed ID: 35546110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
    Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; Klopfer SO; Grandhi A; Eves K; Hepler D; Robertson MN; Hwang C; Hanna GJ; Correll T
    J Acquir Immune Defic Syndr; 2022 Sep; 91(1):68-72. PubMed ID: 35972855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.
    Cilento ME; Wen X; Reeve AB; Ukah OB; Snyder AA; Carrillo CM; Smith CP; Edwards K; Wahoski CC; Kitzler DR; Kodama EN; Mitsuya H; Parniak MA; Tedbury PR; Sarafianos SG
    Viruses; 2023 Sep; 15(10):. PubMed ID: 37896768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
    Asante-Appiah E; Lai J; Wan H; Yang D; Martin EA; Sklar P; Hazuda D; Petropoulos CJ; Walworth C; Grobler JA
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0121621. PubMed ID: 34570651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No antagonism or cross-resistance and a high barrier to the emergence of resistance
    Diamond TL; Goh SL; Ngo W; Rodriguez S; Xu M; Klein DJ; Grobler JA; Asante-Appiah E
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0033424. PubMed ID: 38864613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.
    McColl DJ; Margot N; Chen SS; Harris J; Borroto-Esoda K; Miller MD
    HIV Clin Trials; 2011; 12(2):61-70. PubMed ID: 21498149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
    Orkin C; Squires KE; Molina JM; Sax PE; Sussmann O; Lin G; Kumar S; Hanna GJ; Hwang C; Martin E; Teppler H
    Clin Infect Dis; 2021 Jul; 73(1):33-42. PubMed ID: 33336698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy.
    Aulicino PC; Sharma S; Truong K; Kukunoor V; Ghei K; Arazi-Caillaud S; Taicz M; Bologna R; Mangano A; Kimata JT
    J Antimicrob Chemother; 2024 Feb; 79(2):370-374. PubMed ID: 38153245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2021 Jul; 76(8):2137-2142. PubMed ID: 33855437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
    Borroto-Esoda K; Parkin N; Miller MD
    Antivir Chem Chemother; 2007; 18(5):297-300. PubMed ID: 18046962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
    Cilento ME; Reeve AB; Michailidis E; Ilina TV; Nagy E; Mitsuya H; Parniak MA; Tedbury PR; Sarafianos SG
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0116721. PubMed ID: 34516245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
    Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; DeJesus E; Olsen Klopfer S; Grandhi A; Eves K; Robertson MN; Correll T; Hwang C; Hanna GJ; Sklar P
    Lancet HIV; 2021 Jun; 8(6):e324-e333. PubMed ID: 34000227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Tabassum T; Azeem SM; Muwonge AN; Frey KM
    Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
    Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
    Miller MD; Haddad M; Su C; Gibbs C; McColl DJ; Guyer B
    Antivir Ther; 2012; 17(6):993-9. PubMed ID: 22837442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
    Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.